Ozempic in Spain: what it is, how it works and who can take it

Reading time: 10 minutes. Last updated: April 2026. Reviewed by Dr. David Céspedes, Specialist in Preventive Medicine and Longevity.

Introduction

Ozempic is probably the medicine you have heard the most about in the last two years. It appears in office conversations, in press headlines, in social media threads. And yet, a large part of the information circulating about it is imprecise, contradictory or directly incorrect.

This guide answers with clinical rigour the questions that really matter about Ozempic in Spain: what it is exactly, how it works in the body, who is a candidate to take it, how it is obtained legally, what risks it has and what alternatives exist. All the information is updated to 2026 and reviewed by Dr. David Céspedes, a licensed endocrinologist specialised in preventive medicine and longevity.

What Ozempic is: factsheet in plain language

Ozempic® is the trade name of semaglutide, a molecule developed by the Danish pharmaceutical company Novo Nordisk. Technically it belongs to a pharmacological category called GLP-1 receptor agonists, which means that it mimics the effect of a natural hormone of the human body (glucagon-like peptide 1, or GLP-1).

Semaglutide is administered by weekly subcutaneous injection, generally in the abdomen, thigh or arm, with a pre-filled pen device that facilitates self-administration.

From a regulatory point of view, Ozempic has been authorised in the European Union by the European Medicines Agency (EMA) since 2018, and in Spain by the AEMPS. Its official authorised indication is the treatment of type 2 diabetes mellitus in adults, in combination with diet and exercise, when glycaemic control is not achieved with other treatments.

Ozempic and weight loss: off-label use

Although Ozempic is officially authorised for type 2 diabetes, clinical trials showed that diabetic patients taking it experienced significant weight losses as an additional effect. This finding led Novo Nordisk to develop a second medicine with the same active ingredient (semaglutide) but at higher doses, specifically indicated for weight loss: Wegovy®.

In Spain, the key difference is:

• Ozempic: authorised for type 2 diabetes. Maximum dose of 1 mg weekly.
• Wegovy: authorised for obesity and overweight with comorbidities. Maximum dose of 2.4 mg weekly.

The use of Ozempic for weight loss in non-diabetic patients is considered off-label use (outside indication). This means that a doctor may prescribe it under their clinical responsibility in certain circumstances, but it is not covered by Social Security and requires documented clinical justification.

How Ozempic works in the body

Semaglutide acts on several systems simultaneously, which explains why it is so effective both in glycaemic control and in reducing body weight.

Action on the pancreas

It stimulates the secretion of insulin only when blood glucose levels are elevated. This reduces the risk of hypoglycaemia compared to other antidiabetic medications. Simultaneously, it suppresses the release of glucagon, the hormone that raises glucose levels.

Action on the stomach

It slows gastric emptying, which prolongs the feeling of satiety after meals. Treated patients report feeling full with smaller portions and taking longer to feel hungry again.

Action on the brain

It acts directly on receptors in the hypothalamus involved in the regulation of appetite and the feeling of hunger. This central mechanism is key in the reduction of body weight and explains why patients describe a real decrease in obsessive thinking about food, popularly known as food noise.

Clinical profiles who are candidates for Ozempic

The prescription of Ozempic requires individualised medical evaluation. Not all patients are candidates, and some conditions can absolutely contraindicate it. The profiles where clinical evidence supports its use include:

• Patients with type 2 diabetes not controlled with metformin and other oral antidiabetics.
• Patients with type 2 diabetes and high cardiovascular risk, since Ozempic has demonstrated reduction of major cardiovascular events.
• Patients with obesity (BMI ≥ 30) or overweight with comorbidities (BMI ≥ 27 with hypertension, dyslipidemia, sleep apnoea, etc.), although for this profile the official indication is Wegovy, not Ozempic.

Absolute contraindications

• Personal or family history of medullary thyroid carcinoma.
• Multiple endocrine neoplasia type 2 syndrome (MEN 2).
• Known hypersensitivity to semaglutide or any excipient.
• Pregnancy and breastfeeding.
• Active acute or chronic pancreatitis.

Profiles that require especially careful evaluation

• Patients with kidney or liver disease.
• Patients with advanced diabetic retinopathy.
• Patients with a history of pancreatitis or biliary pathology.
• Patients with active eating disorders.

How Ozempic is obtained legally in Spain

Ozempic is a medicine subject to mandatory medical prescription. This means that:

• It cannot be acquired without a medical prescription issued by an authorised healthcare professional.
• It cannot be sold online without a prescription. Any website that offers Ozempic without a prescription operates illegally and the product may be counterfeit.
• Dispensation must take place in legally authorised pharmacies.

The legitimate routes of access are:

Via public healthcare

Only for patients with type 2 diabetes who meet specific inclusion criteria in the service portfolio of the National Health System. The primary care doctor or endocrinologist evaluates suitability and issues a funded electronic prescription.

Via private in-person medical consultation

The patient goes to a private endocrinologist, performs a complete clinical evaluation, and if the doctor considers the treatment indicated, issues an electronic private prescription that is dispensed at a pharmacy. The cost includes consultation plus medication at the patient's expense.

Via private telemedicine with a licensed doctor

Emerging model that allows online consultation with an endocrinologist licensed in Spain, clinical evaluation through a structured questionnaire and videoconference, and if appropriate, issuance of an electronic private prescription that the patient collects at their usual pharmacy. This model is only legitimate if the prescribing doctor is licensed in Spain with a verifiable number.

What to look for in a supervised medical programme

If you are considering starting treatment with Ozempic or any other GLP-1 receptor agonist, it is worth rigorously evaluating the medical programme you turn to. The elements that distinguish a serious medical programme are:

• Identifiable prescribing doctor, with a registration number verifiable in the Register of Licensed Doctors.
• Relevant specialty of the doctor: endocrinology, preventive medicine, internal medicine, or family medicine with specific training in obesity.
• Complete clinical evaluation before prescribing, including medical history, updated lab tests and assessment of contraindications.
• Progressive dose titration during the first weeks to minimise side effects.
• Continuous medical follow-up, ideally monthly, to adjust doses and evaluate response.
• Accessible support to resolve doubts or manage side effects between consultations.
• Complementary nutritional plan and supplementation recommendations appropriate to the caloric deficit.

Conclusion

Ozempic is an effective medicine with solid clinical evidence for the indications for which it is authorised. But it is not a consumer product nor a magical solution. It is a drug subject to medical prescription for important clinical reasons: it has real contraindications, manageable but present side effects, and its efficacy critically depends on its being used under adequate medical supervision.

Before considering any pharmacological treatment for weight loss, the clinical recommendation is to go to a specialised endocrinologist who will evaluate your individual case, review your complete history, consider your particular conditions and design the most appropriate plan for your profile.

Are you considering a medical approach to your weight loss?

FitRX is a comprehensive medical programme designed precisely to offer professional and safe access to bariatric medicine. Dr. David Céspedes, a licensed endocrinologist, evaluates your individual case in less than 24 hours and designs a personalised plan according to your clinical profile. If you are not a candidate, there is no charge.

👉 Start your medical evaluation

Frequently asked questions

Can Ozempic be bought without a prescription in Spain?

No. Ozempic is a medicine subject to mandatory medical prescription. Its dispensation without a prescription is illegal and websites that offer it without a prescription operate outside the legal framework. In addition, the product acquired through non-official routes may be counterfeit or poorly stored.

How much does Ozempic cost in Spain?

The price varies according to dose and whether the medicine is funded or not. With a private prescription, the approximate cost is between €120 and €200 per monthly pen, depending on presentation. In cases funded by Social Security for type 2 diabetes, the patient only pays the corresponding contribution.

How much weight is lost with Ozempic?

Weight loss is variable and depends on the patient, the dose, the duration of treatment and the accompanying lifestyle modifications. Clinical trials with semaglutide show mean losses between 10% and 15% of initial body weight at 68 weeks of supervised treatment.

What happens when you stop taking Ozempic?

Studies show that after suspending treatment there is partial regain of lost weight if lifestyle modifications are not maintained. That is why continuous medical follow-up and the nutritional plan are as important as the medication itself.

Can I take Ozempic just to lose weight if I do not have diabetes?

This decision is exclusively medical. For weight loss without diabetes, the official indication in Spain is Wegovy, not Ozempic. A doctor may prescribe Ozempic off-label under their clinical criteria in certain circumstances, but it requires documented justification and rigorous follow-up.

Legal notice

This content is informative and educational. It does not replace professional medical advice, diagnosis or treatment under any circumstances. The medicines mentioned in this article are drugs subject to medical prescription whose dispensation requires an official prescription issued by an authorised healthcare professional. Always consult an endocrinologist before starting any treatment for weight loss.